Maven Securities LTD Dexcom Inc Transaction History

Maven Securities LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$84.98 - $122.67 $282,728 - $408,123	-3,327 Reduced 63.89%	1,880 $212,000
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $67,035 - $82,690	-878 Reduced 14.43%	5,207 $4.19 Million
Q2 2022 Aug 15, 2022	BUY	$67.99 - $132.89 $357,627 - $699,001	5,260 Added 637.58%	6,085 $454,000
Q1 2022 May 16, 2022	BUY	$94.08 - $130.2 $22,955 - $31,768	244 Added 42.0%	825 $422,000
Q4 2021 Feb 14, 2022	BUY	$129.87 - $162.82 $22,077 - $27,679	170 Added 41.36%	581 $312,000
Q3 2021 Nov 15, 2021	SELL	$106.71 - $143.18 $322,477 - $432,689	-3,022 Reduced 88.03%	411 $225,000
Q2 2021 Aug 16, 2021	BUY	$80.99 - $107.93 $225,233 - $300,153	2,781 Added 426.53%	3,433 $1.47 Million
Q1 2021 May 17, 2021	SELL	$84.79 - $104.74 $368,666 - $455,409	-4,348 Reduced 86.96%	652 $234,000
Q4 2020 Feb 12, 2021	BUY	$78.0 - $104.5 $390,000 - $522,500	5,000 New	5,000 $1.85 Million
Q4 2018 Feb 14, 2019	SELL	$26.99 - $37.37 $102,562 - $142,006	-3,800 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$23.35 - $36.72 $88,730 - $139,536	3,800 New	3,800 $549,000

1,023

353M

5.51M

5.61M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $33.5B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.